Business Context and Reporting Period
This Form 8-K filing by Aziyo Biologics, Inc. (trading symbol: AZYO) reports on events occurring between October 7, 2020, and October 13, 2020. The filing details the closing of the Company's Initial Public Offering (IPO) and the concurrent amendment of its corporate governance documents, including the Restated Certificate of Incorporation and Amended and Restated Bylaws.
Key Financial Metrics
- Gross Proceeds: Approximately $50.0 million from the IPO.
- Offering Price: $17.00 per share.
- Shares Issued: 2,205,882 shares of Class A common stock and 735,294 shares of Class B common stock.
- Over-Allotment Option: Underwriters granted an option to purchase up to an additional 441,176 shares of Class A common stock.
- Net Proceeds: The filing does not provide a specific dollar value for net proceeds after deducting underwriting discounts, commissions, and estimated offering expenses.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, profit, operating cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the transition from a private to a public company via the IPO. Additionally, the Company amended its Certificate of Incorporation to:
- Authorize 200,000,000 shares of Class A common stock and 20,000,000 shares of Class B common stock.
- Eliminate all references to previously existing preferred stock.
- Establish a classified board of directors with staggered three-year terms.
- Restrict director removal to "for cause" only, requiring a two-thirds vote of capital stock holders.
- Eliminate the ability of stockholders to take action by written consent.
- Designate the Court of Chancery of Delaware as the exclusive forum for certain corporate actions and federal district courts for Securities Act claims.
Outlook, Management Commentary, and Risks
Use of Proceeds: Management intends to use net proceeds to hire additional sales personnel, expand marketing programs, fund product development and clinical research, and for working capital and general corporate purposes. The Company may also use a portion of proceeds to acquire, in-license, or invest in complementary products or technologies, though no agreements exist as of the filing date.
Risks and Contingencies: The filing notes that the exclusive forum provisions for legal actions do not apply to actions vested in the exclusive jurisdiction of other courts or forums, including those enforcing liabilities under the Securities Act of 1933 or the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the exact amount of net proceeds after deducting underwriting discounts and offering expenses.
- Review the full text of the Restated Certificate of Incorporation (Exhibit 3.1) and Amended and Restated Bylaws (Exhibit 3.2) for specific governance restrictions.
- Confirm the exercise status of the 441,176 share over-allotment option granted to underwriters.
- Monitor future filings for details on the specific allocation of funds toward product development and clinical research.